Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors

Journal of Medicinal Chemistry

Volumn 53, Issue 11, 2010, Pages 4399-4411

  Höfgen, Norbert ^a   Stange, Hans ^a   Schindler, Rudolf ^a   Lankau, Hans Joachim ^a   Grunwald, Christian ^a   Langen, Barbara ^a   Egerland, Ute ^a   Tremmel, Peter ^a   Pangalos, Menelas N ^b   Marquis, Karen L ^b   Hage, Thorsten ^a   Harrison, Boyd L ^b   Malamas, Michael S ^b   Brandon, Nicholas J ^b   Kronbach, Thomas ^a  

^a Biotie Therapies GmbH   (Germany)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIMETHYL 8 METHOXY 1 PROPYL IMIDAZO[1,5 A]PYRIDO[3,2 E]PYRAZINE; 8 METHOXY 3 METHYL 4 METHYLSULFONYLAMINO 1 PROPYLIMIDAZO[1,5 A]PYRIDO[3,2 E]PYRAZINE; CLOZAPINE; CYCLIC AMP; DIZOCILPINE; IMIDAZO[1,5 A]PYRIDO[3,2 E]PYRAZINE; IMIDAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PAPAVERINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE INHIBITOR; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HYDROLYSIS; HYPERACTIVITY; NONHUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; SCHIZOPHRENIA; STEREOTYPY;

ANIMALS; DRUG DISCOVERY; FEMALE; HUMANS; MODELS, MOLECULAR; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTEIN CONFORMATION; PYRAZINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RATS, WISTAR;

EID: 77953206436     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1002793     Document Type: Article

References (38)

1. Conti, M.; Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling Annu. Rev. Biochem. 2007, 76, 481-511
2. Bender, A. T.; Beavo, J. A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use Pharmacol. Rev. 2006, 58, 488-520
3. Essayan, D. M. Cyclic nucleotide phosphodiesterases J. Allergy Clin. Immunol. 2001, 108, 671-680
4. Houslay, M. D.; Adams, D. R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization Biochem. J. 2003, 370, 1-18
5. Coskran, T. M.; Morton, D.; Menniti, F. S.; Adamowicz, W. O.; Kleiman, R. J.; Ryan, A. M.; Strick, C. A.; Schmidt, C. J.; Stephenson, D. T. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species J. Histochem. Cytochem. 2006, 54, 1205-1213
6. Seeger, T. F.; Bartlett, B.; Coskran, T. M.; Culp, J. S.; James, L. C.; Krull, D. L.; Lanfear, J.; Ryan, A. M.; Schmidt, C. J.; Strick, C. A.; Varghese, A. H.; Williams, R. D.; Wylie, P. G.; Menniti, F. S. Immunohistochemical localization of PDE10A in the rat brain Brain Res. 2003, 985, 113-126
7. Xie, Z.; Adamowicz, W. O.; Eldred, W. D.; Jakowski, A. B.; Kleiman, R. J.; Morton, D. G.; Stephenson, D. T.; Strick, C. A.; Williams, R. D.; Menniti, F. S. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase Neuroscience 2006, 139, 597-607
8. Lapiz, M. D.; Fulford, A.; Muchimapura, S.; Mason, R.; Parker, T.; Marsden, C. A. Influence of postweaning social isolation in the rat on brain development, conditioned behavior, and neurotransmission Neurosci. Behav. Physiol. 2003, 33, 13-29
9. Siuciak, J. A.; McCarthy, S. A.; Chapin, D. S.; Fujiwara, R. A.; James, L. C.; Williams, R. D.; Stock, J. L.; McNeish, J. D.; Strick, C. A.; Menniti, F. S.; Schmidt, C. J. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function Neuropharmacology 2006, 51, 374-385
10. Siuciak, J. A.; Chapin, D. S.; Harms, J. F.; Lebel, L. A.; McCarthy, S. A.; Chambers, L.; Shrikhande, A.; Wong, S.; Menniti, F. S.; Schmidt, C. J. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis Neuropharmacology 2006, 51, 386-396
11. Kostowski, W.; Gajewska, S.; Bidzinski, A.; Hauptman, M. Papaverine, drug-induced stereotypy and catalepsy and biogenic amines in the brain of the rat Pharmacol., Biochem. Behav. 1976, 5, 15-17
12. Rodefer, J. S.; Murphy, E. R.; Baxter, M. G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats Eur. J. Neurosci. 2005, 21, 1070-1076
13. Pandit, J. Crystal structure of 3′,5′-cyclic nucleotide phosphodiesterase (PDE10A) and uses thereof. U.S. Patent 2005/0202550 A1, 2005.
14. Siuciak, J. A.; Chapin, D. S.; McCarthy, S. A.; Harms, J. F.; Fox, C. B.; Chappie, T. A.; Humphrey, J. M.; Proulz, C.; Verhoest, P. R.; Schmidt, C. J. Novel potent and selective phosphodiesterase 10A (PDE10A) inhibitors show activity in animal models of psychosis. Society for Neuroscience Annual Meeting, Atlanta, GA, 2006.
15. Chappie, T.; Humphrey, J.; Menniti, F.; Schmidt, C. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape Curr. Opin. Drug Discovery Dev. 2009, 12, 458-467
16. Kehler, J.; Ritzen, A.; Greve, D. R. The potential therapeutic use of phosphodiesterase 10 inhibitors Expert. Opin. Ther. Patents 2007, 17, 147-158
17. Norris, D.; Chen, P.; Barrish, J. C.; Das, J.; Moquin, R.; Chen, B.-C.; Guo, P. Synthesis of imidazo[1,5-a]quinoxalin-4(5 H)-one template via a novel intramolecular cyclization process Tetrahedron Lett. 2001, 42, 4297-4299
18. Free, S. M., Jr.; Wilson, J. W. A mathematical contribution to structure-activity studies J. Med. Chem. 1964, 53, 395-399
19. Fujita, T.; Ban, T. Structure-activity study of phenethylamines as substrates of biosynthetic enzymes of sympathetic transmitters J. Med. Chem. 1971, 14, 148-152
20. Benigni, R.; Giuliani, A.; Gruska, A.; Franke, R. Introductory discussion on QSAR. In Quantitative Structure-Activity Relationship (QSAR) Models of Mutagens and Carcinogens; Benigni, R., Ed.; CRC Press: Boca Raton, FL, 2003; pp 1-38.
21. Chappie, T. A.; Humphrey, J. M.; Allen, M. P.; Estep, K. G.; Fox, C. B.; Lebel, L. A.; Liras, S.; Marr, E. S.; Menniti, F. S.; Pandit, J.; Schmidt, C. J.; Tu, M.; Williams, R. D.; Yang, F. V. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors J. Med. Chem. 2007, 50, 182-185
22. Huai, Q.; Wang, H.; Sun, Y.; Kim, H. Y.; Liu, Y.; Ke, H. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity Structure 2003, 11, 865-873
23. Andersen, O. A.; Schonfeld, D. L.; Toogood-Johnson, I.; Felicetti, B.; Albrecht, C.; Fryatt, T.; Whittaker, M.; Hallett, D.; Barker, J. Cross-linking of protein crystals as an aid in the generation of binary protein-ligand crystal complexes, exemplified by the human PDE10a-papaverine structure Acta Crystallogr., Sect. D: Biol. Crystallogr. 2009, 65, 872-874
24. Conti, M. A view into the catalytic pocket of cyclic nucleotide phosphodiesterases Nat. Struct. Mol. Biol. 2004, 11, 809-810
25. Ke, H.; Wang, H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity Curr. Top. Med. Chem. 2007, 7, 391-403
26. Verhoest, P. R.; Chapin, D. S.; Corman, M.; Fonseca, K.; Harms, J. F.; Hou, X.; Marr, E. S.; Menniti, F. S.; Nelson, F.; O'Connor, R.; Pandit, J.; Proulx-LaFrance, C.; Schmidt, A. W.; Schmidt, C. J.; Suiciak, J. A.; Liras, S. Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1 H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia J. Med. Chem. 2009, 52, 5188-5196
27. Zhang, K. Y.; Card, G. L.; Suzuki, Y.; Artis, D. R.; Fong, D.; Gillette, S.; Hsieh, D.; Neiman, J.; West, B. L.; Zhang, C.; Milburn, M. V.; Kim, S. H.; Schlessinger, J.; Bollag, G. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases Mol. Cell 2004, 15, 279-286
28. Andiné, P.; Widermark, N.; Axelsson, R.; Nyberg, G.; Olofsson, U.; Martensson, E. and Sandberg, M. Characterization of MK-801-induced behavior as a putative rat model of psychosis J. Pharmacol. Exp. Ther. 1999, 290, 1393-1408
29. Capuano, B.; Crosby, I. T.; Lloyd, E. J. Schizophrenia: genesis, receptorology and current therapeutics Curr. Med. Chem. 2002, 9, 521-548
30. Chen, P.; Norris, D. J.; Barrish, J. C.; Iwanowicz, E. J.; Gu, H. H.; Schieven, G. L. Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors. Patent WO/1999/045009, 1998
31. SigmaStat, version 3.11; Systat Software, Inc.: Chicago, 2004.
32. SigmaPlot 2004, version 9.0; Systat Software, Inc.: Chicago, 2004.
33. Grunwald, C.; Rundfeldt, C.; Lankau, H. J.; Arnold, T.; Höfgen, N.; Dost, R.; Egerland, U.; Hofmann, H. J.; Unverferth, K. Synthesis, Pharmacology, and Structure-Activity Relationships of Novel Imidazolones and Pyrrolones as Modulators of GABA(A) Receptors J. Med. Chem. 2006, 49, 1855-1866
34. Corina, version 1.82; Oxford Molecular Group: The Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK, 2000.
35. Clark, T.; Alex, A.; Beck, B.; Chandrasekhar, J.; Gedeck, P.; Horn, A.; Hutter, M.; Martin, B.; Rauhut, G.; Sauer, W.; Schindler, T.; Steinke, T. VAMP, version 7.5a; The Oxford Molecular Group: The Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK, 1999.
36. TSAR 3D, version 3.3; Oxford Molecular Ltd (now Accelrys): The Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK, 2000.
37. GOLD, version 4.1.2; CCDC Software Ltd.: Cambridge, UK, 2010.
38. Wallace, A. C.; Laskowski, R. A.; Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions Protein Eng. 1995, 8, 127-134